Teacher Retirement System of Texas Has $258,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Teacher Retirement System of Texas grew its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 17.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 13,708 shares of the company’s stock after acquiring an additional 2,034 shares during the quarter. Teacher Retirement System of Texas’ holdings in Pacira BioSciences were worth $258,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Wealthfront Advisers LLC bought a new stake in Pacira BioSciences during the fourth quarter worth about $1,001,000. AlphaQuest LLC increased its stake in Pacira BioSciences by 43.4% in the fourth quarter. AlphaQuest LLC now owns 13,493 shares of the company’s stock valued at $254,000 after acquiring an additional 4,083 shares during the last quarter. Amundi raised its position in Pacira BioSciences by 200.8% during the fourth quarter. Amundi now owns 23,114 shares of the company’s stock valued at $429,000 after purchasing an additional 15,431 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares during the last quarter. Finally, Banco Santander S.A. boosted its holdings in shares of Pacira BioSciences by 5.8% in the 4th quarter. Banco Santander S.A. now owns 126,900 shares of the company’s stock valued at $2,391,000 after purchasing an additional 6,900 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PCRX shares. Barclays boosted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. HC Wainwright lifted their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC upped their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and upped their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Trading Down 3.1 %

NASDAQ PCRX opened at $24.07 on Wednesday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $1.11 billion, a PE ratio of -11.86 and a beta of 0.86. The business’s 50-day moving average price is $24.84 and its two-hundred day moving average price is $20.17.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.